Phaseline

Targets › GMCSF

GMCSF (Granulocyte-macrophage colony-stimulating factor): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.

Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. (UniProt, P04141)

Open in Phaseline: the race on GMCSF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Talimogene Laherparepvec
ICP34.5- and ICP47-deleted herpes simplex virus 1 (HSV-1) expressing human GM-CSF
GMCSFPhase 2Advanced Melanoma; Leiomyosarcoma; Anaplastic Large Cell Lymphoma, ALK-NegativeDec 2026

Conditions

Advanced Melanoma (1) Leiomyosarcoma (1) Anaplastic Large Cell Lymphoma, ALK-Negative (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.